Prognostic value of microRNA-495-3p, adiponectin, and cardiometabolic index in type 2 diabetic nephropathy.

IF 4.6 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

World Journal of Diabetes Pub Date : 2025-07-15 DOI:10.4239/wjd.v16.i7.108262

Xu-Chun Xu, He-Jing Fang, Hua-Ying Huang

{"title":"Prognostic value of microRNA-495-3p, adiponectin, and cardiometabolic index in type 2 diabetic nephropathy.","authors":"Xu-Chun Xu, He-Jing Fang, Hua-Ying Huang","doi":"10.4239/wjd.v16.i7.108262","DOIUrl":null,"url":null,"abstract":"Background: Type 2 diabetic nephropathy (T2DN) is a severe complication of diabetes mellitus, and identifying biomarkers for its prognosis remains a critical challenge. Previous studies have suggested potential roles of microRNAs (e.g., miR-495-3p), adiponectin (ADPN), and cardiometabolic index (CMI) in metabolic and renal pathologies. However, their combined predictive value for T2DN prognosis is not well understood.Aim: To explore serum miR-495-3p, ADPN, and CMI levels in T2DN and their value in predicting prognosis.Methods: A total of 98 T2DN patients (study group) and 49 type 2 diabetic patients with normal renal function (control group) were enrolled from February 2020 to February 2022. Serum levels of miR-495-3p, ADPN, and CMI were measured in both groups. Patients were followed up for 6 months to assess prognosis. Differences between groups were analyzed, and multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed to evaluate the predictive value of these biomarkers.Results: The study group exhibited significantly lower miR-495-3p levels and higher ADPN and CMI levels compared to the control group (P < 0.05). Poor prognosis patients had even lower miR-495-3p and higher ADPN and CMI levels than those with good prognosis (P < 0.05). Multivariate analysis identified alanine aminotransferase, aspartate aminotransferase, urea nitrogen, serum creatinine, miR-495-3p, ADPN, and CMI as independent predictors of prognosis (P < 0.05). ROC analysis revealed area under the curve values of 0.762 (miR-495-3p), 0.902 (ADPN), 0.757 (CMI), 0.899 (alanine aminotransferase), 0.852 (aspartate aminotransferase), 0.916 (urea nitrogen), and 0.910 (serum creatinine) for predicting poor prognosis (P < 0.05).Conclusion: Low miR-495-3p and high ADPN and CMI levels are linked to T2DN and poor prognosis, highlighting their potential for risk prediction and clinical management.","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 7","pages":"108262"},"PeriodicalIF":4.6000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278069/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v16.i7.108262","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 diabetic nephropathy (T2DN) is a severe complication of diabetes mellitus, and identifying biomarkers for its prognosis remains a critical challenge. Previous studies have suggested potential roles of microRNAs (e.g., miR-495-3p), adiponectin (ADPN), and cardiometabolic index (CMI) in metabolic and renal pathologies. However, their combined predictive value for T2DN prognosis is not well understood.

Aim: To explore serum miR-495-3p, ADPN, and CMI levels in T2DN and their value in predicting prognosis.

Methods: A total of 98 T2DN patients (study group) and 49 type 2 diabetic patients with normal renal function (control group) were enrolled from February 2020 to February 2022. Serum levels of miR-495-3p, ADPN, and CMI were measured in both groups. Patients were followed up for 6 months to assess prognosis. Differences between groups were analyzed, and multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed to evaluate the predictive value of these biomarkers.

Results: The study group exhibited significantly lower miR-495-3p levels and higher ADPN and CMI levels compared to the control group (P < 0.05). Poor prognosis patients had even lower miR-495-3p and higher ADPN and CMI levels than those with good prognosis (P < 0.05). Multivariate analysis identified alanine aminotransferase, aspartate aminotransferase, urea nitrogen, serum creatinine, miR-495-3p, ADPN, and CMI as independent predictors of prognosis (P < 0.05). ROC analysis revealed area under the curve values of 0.762 (miR-495-3p), 0.902 (ADPN), 0.757 (CMI), 0.899 (alanine aminotransferase), 0.852 (aspartate aminotransferase), 0.916 (urea nitrogen), and 0.910 (serum creatinine) for predicting poor prognosis (P < 0.05).

Conclusion: Low miR-495-3p and high ADPN and CMI levels are linked to T2DN and poor prognosis, highlighting their potential for risk prediction and clinical management.

查看原文本刊更多论文

microRNA-495-3p、脂联素和心脏代谢指数在2型糖尿病肾病中的预后价值

背景：2型糖尿病肾病（T2DN）是糖尿病的严重并发症，确定其预后的生物标志物仍然是一个关键的挑战。先前的研究表明，microrna（如miR-495-3p）、脂联素（ADPN）和心脏代谢指数（CMI）在代谢和肾脏病理中的潜在作用。然而，它们对T2DN预后的综合预测价值尚不清楚。目的：探讨T2DN患者血清miR-495-3p、ADPN、CMI水平及其对预后的预测价值。方法：于2020年2月~ 2022年2月选取T2DN患者98例（研究组）和肾功能正常的2型糖尿病患者49例（对照组）。检测两组血清miR-495-3p、ADPN和CMI水平。随访6个月，评估预后。分析各组间差异，采用多变量logistic回归和受试者工作特征（ROC）曲线分析来评价这些生物标志物的预测价值。结果：研究组miR-495-3p水平明显低于对照组，ADPN、CMI水平明显高于对照组（P < 0.05）。预后差的患者miR-495-3p水平低于预后好的患者，ADPN、CMI水平高于预后好的患者（P < 0.05）。多因素分析发现丙氨酸转氨酶、天冬氨酸转氨酶、尿素氮、血清肌酐、miR-495-3p、ADPN和CMI是预后的独立预测因子（P < 0.05）。ROC分析显示，曲线下面积0.762 （miR-495-3p）、0.902 （ADPN）、0.757 （CMI）、0.899（丙氨酸转氨酶）、0.852（天冬氨酸转氨酶）、0.916（尿素氮）、0.910（血清肌酐）预测预后不良（P < 0.05）。结论：低miR-495-3p和高ADPN、CMI水平与T2DN及不良预后相关，具有潜在的风险预测和临床管理价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

自引率

2.40%

发文量

909

期刊介绍： The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.